SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Guilford (GLFD) - Steadily Rising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: NeuroInvestment who wrote (258)11/23/1998 10:14:00 AM
From: Steve  Read Replies (1) of 496
 
Interesting article in Sunday's (11/22/98) Los Angeles Times regarding small biotechs. The article is right on point as to my feeling regarding GLFD--the environment for small biotechs has changed. Read the article. I hope Dr. Smith does. GLFD must be sold now instead of waiting until when they have $20 million in cash, and either another delay or failure behind them. Point being that by the time they need more cash they still won't have earnings. They probably won't be able to raise money. Even the 10-Q says that they will have to raise money in the future.

A final point. If I recall correctly, in Dr. Smith's opening letter in the 1997 annual report, he boasts how GLFD scientist are more productive in discovery than large pharmaceuticals. If that is true, then GLFD should attract investor's capital since the efficient allocation of capital theory dictates this. It seems like it won't be capital via the stock market. Therefore it must be capital via a private buyout.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News